| human | Q5 |
| P9913 | FLORE author ID | 17541 |
| P9843 | IRIS UNINA author ID | 62370 |
| P496 | ORCID iD | 0000-0003-3325-3760 |
| P1153 | Scopus author ID | 7103061535 |
| P9914 | USiena air author ID | 11738 |
| P69 | educated at | University of Florence | Q820887 |
| P108 | employer | University of Florence | Q820887 |
| Careggi University Hospital | Q913126 | ||
| P734 | family name | Amato | Q3613700 |
| Amato | Q3613700 | ||
| Amato | Q3613700 | ||
| P735 | given name | Maria Pia | Q23498529 |
| Maria Pia | Q23498529 | ||
| P106 | occupation | neurologist | Q783906 |
| P39 | position held | full professor | Q25339110 |
| P21 | sex or gender | female | Q6581072 |
| Q47872883 | "Brain reserve" and "cognitive reserve" should always be taken into account when studying neurodegeneration - Commentary. |
| Q41369774 | A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis. |
| Q35809567 | A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients |
| Q57911911 | A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN |
| Q73094188 | A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials |
| Q51873437 | A short version of Rao's Brief Repeatable Battery as a screening tool for cognitive impairment in multiple sclerosis. |
| Q52152219 | Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis. |
| Q48177354 | Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. |
| Q40542938 | Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes |
| Q35480805 | Altered cerebellar functional connectivity mediates potential adaptive plasticity in patients with multiple sclerosis. |
| Q47974952 | Anxiety state affects information processing speed in patients with multiple sclerosis |
| Q58451959 | ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis |
| Q48235116 | Appraisal of brain connectivity in radiologically isolated syndrome by modeling imaging measures |
| Q30835239 | Assessing executive function with the D-KEFS sorting test: normative data for a sample of the Italian adult population. |
| Q58452046 | Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis |
| Q59389207 | Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience |
| Q58452048 | Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases |
| Q52967863 | Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. |
| Q58452055 | Benign multiple sclerosis |
| Q47560647 | Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers |
| Q48481098 | Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis |
| Q34342312 | Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome |
| Q34338582 | Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. |
| Q59649467 | COGNITIVE AND PSYCHOSOCIAL FEATURES OF CHILDHOOD AND JUVENILE MS |
| Q93672474 | CT signs relevant to the diagnosis of tuberculous meningitis: contrast uptake at tentorial level |
| Q57602019 | Can the Expanded Disability Status Scale be assessed by telephone? |
| Q50903977 | Caregiver quality of life in multiple sclerosis: a multicentre Italian study. |
| Q31038347 | Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study |
| Q49238826 | Changes in neuropsychological test performance over the workday in multiple sclerosis. |
| Q30889903 | Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis |
| Q38167399 | Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe. |
| Q81198330 | Clinical correlations of CSF single IgG bands |
| Q47892293 | Clinical outcome measures for progressive MS trials. |
| Q36766028 | Clinical outcome measures in multiple sclerosis. |
| Q84843574 | Cognitive and psychosocial issues in pediatric multiple sclerosis: where we are and where we need to go |
| Q48952813 | Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. |
| Q33377548 | Cognitive changes in multiple sclerosis |
| Q84659411 | Cognitive dysfunction in multiple sclerosis: current approaches to clinical management |
| Q51867115 | Cognitive impairment and event-related potentials in paediatric multiple sclerosis: 2-year study. |
| Q72526361 | Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up |
| Q90847542 | Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors |
| Q48457691 | Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions |
| Q37799568 | Cognitive impairment in pediatric multiple sclerosis |
| Q45214546 | Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes |
| Q43866034 | Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study. |
| Q41721827 | Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis |
| Q48435815 | Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. |
| Q40724148 | Contribution of different relapse phenotypes to disability in multiple sclerosis. |
| Q51873135 | Coping strategies, psychological variables and their relationship with quality of life in multiple sclerosis. |
| Q48523698 | Correction to: Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach |
| Q34231830 | Cortical lesions in radiologically isolated syndrome. |
| Q38125249 | Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. |
| Q38843046 | Defining secondary progressive multiple sclerosis |
| Q104284186 | Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study |
| Q81475298 | Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment |
| Q96683766 | Disease-modifying therapy aids cognition in multiple sclerosis |
| Q40780434 | Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound. |
| Q47849889 | ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis |
| Q52391534 | ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. |
| Q41930141 | Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus. |
| Q36226967 | Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. |
| Q40326260 | Effect of organizational features on patient satisfaction with care in Italian multiple sclerosis centres |
| Q50569165 | Effectiveness of azathioprine treatment in multiple sclerosis. |
| Q37235845 | Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity |
| Q48004049 | Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). |
| Q47891502 | Emotional and neutral verbal memory impairment in Multiple Sclerosis |
| Q48192097 | Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. |
| Q38663577 | Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop |
| Q34527935 | Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. |
| Q59389189 | Erratum to: Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group |
| Q36475759 | Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. |
| Q59649498 | European validation of a standardized clinical description of multiple sclerosis |
| Q48725228 | Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. |
| Q34409412 | Evolving expectations around early management of multiple sclerosis |
| Q38379249 | Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs |
| Q41369754 | Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis |
| Q53123917 | Fluctuations of MS births and UV-light exposure. |
| Q46431006 | Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. |
| Q34469310 | Geographical variations in sex ratio trends over time in multiple sclerosis. |
| Q48625321 | Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. |
| Q38174450 | Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. |
| Q39139645 | Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. |
| Q48329925 | Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis |
| Q39551764 | History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort. |
| Q40689536 | Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers |
| Q91774090 | Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support |
| Q85633732 | Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation |
| Q42651394 | Immunomodulatory therapies delay disease progression in multiple sclerosis |
| Q33533349 | Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population |
| Q48938924 | Impact of cognitive impairment on coping strategies in multiple sclerosis |
| Q28730321 | Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study |
| Q21560827 | Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis |
| Q37071787 | Increased CD8+ T cell responses to apoptotic T cell-associated antigens in multiple sclerosis |
| Q47735680 | Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis |
| Q38097725 | International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. |
| Q44376086 | Interobserver agreement on Poser's and the new McDonald's diagnostic criteria for multiple sclerosis. |
| Q50861362 | Intranetwork and internetwork functional connectivity abnormalities in pediatric multiple sclerosis. |
| Q39714763 | Is there a future for donepezil therapy in the treatment of multiple sclerosis-related cognitive impairment? |
| Q35749074 | Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene. |
| Q58452042 | Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis |
| Q41219904 | Long-term assessment of no evidence of disease activity in relapsing-remitting MS. |
| Q38850911 | Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis |
| Q48177798 | Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. |
| Q46040058 | Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. |
| Q48582785 | Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II). |
| Q45024189 | Longitudinal follow-up of "benign" multiple sclerosis at 20 years. |
| Q48148715 | MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. |
| Q35653675 | Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS |
| Q47678330 | Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach |
| Q37973392 | Management options in multiple sclerosis-associated fatigue. |
| Q48128231 | Maturational Trajectory of Processing Speed Performance in Pediatric Multiple Sclerosis |
| Q79796065 | Motor evoked potentials in multiple sclerosis patients without walking limitation: amplitude vs. conduction time abnormalities |
| Q49563269 | Multiple sclerosis in 2017: Progress in multiple sclerosis - from diagnosis to therapy |
| Q31038381 | Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. |
| Q35148010 | MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients |
| Q59389216 | Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group—Italian Neurological Society |
| Q56992576 | Natalizumab: a country-based surveillance program |
| Q80332818 | Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment |
| Q48572090 | Neocortical volume decrease in relapsing-remitting multiple sclerosis with mild cognitive impairment |
| Q44785506 | Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. |
| Q59649446 | Neuropsychological features in childhood and juvenile multiple sclerosis: Five-year follow-up |
| Q59649484 | New natural history of interferon-β-treated relapsing multiple sclerosis |
| Q52147931 | No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). |
| Q31162052 | Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study |
| Q40143991 | Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. |
| Q38826724 | Pediatric multiple sclerosis: Cognition and mood. |
| Q34737478 | Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis |
| Q51810980 | Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. |
| Q57911720 | Posterior brain damage and cognitive impairment in pediatric multiple sclerosis |
| Q48333424 | Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs |
| Q45832934 | Predictors and dynamics of postpartum relapses in women with multiple sclerosis. |
| Q35619185 | Predictors of disability worsening in clinically isolated syndrome. |
| Q36367612 | Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study |
| Q50042831 | Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks |
| Q50042843 | Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks |
| Q44157548 | Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire). |
| Q41102123 | Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. |
| Q38821503 | Prognostic indicators in pediatric clinically isolated syndrome |
| Q49934636 | Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations |
| Q35112019 | Radiologically isolated syndrome: 5-year risk for an initial clinical event |
| Q48983171 | Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. |
| Q86716781 | Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient |
| Q36538213 | Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) |
| Q51529045 | Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. |
| Q52151058 | Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. |
| Q36373752 | Relevance of brain lesion location to cognition in relapsing multiple sclerosis |
| Q87134171 | Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis |
| Q58452069 | Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria |
| Q53090722 | Risk of relapse phenotype recurrence in multiple sclerosis. |
| Q47419405 | Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort. |
| Q51260423 | Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. |
| Q59389218 | Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica |
| Q48922719 | Sex as a determinant of relapse incidence and progressive course of multiple sclerosis |
| Q68537537 | Short-term intensive cyclophosphamide treatment in progressive multiple sclerosis |
| Q31141962 | Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study |
| Q34234374 | The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population |
| Q86486447 | The Rao's Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population |
| Q36062456 | The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study. |
| Q46007408 | The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. |
| Q59649437 | The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis |
| Q38357313 | The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. |
| Q47328099 | The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders |
| Q40710140 | The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis |
| Q56804781 | The heritage of glatiramer acetate and its use in multiple sclerosis |
| Q63256823 | The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients |
| Q45108726 | The management of multiple sclerosis in children: a European view |
| Q59649500 | The prevalence of pain in multiple sclerosis: A multicenter cross-sectional study |
| Q33636476 | Three years of experience: the Italian registry and safety data update. |
| Q42368351 | Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. |
| Q47639943 | Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. |
| Q102203793 | Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors |
| Q38062466 | Treatment of cognitive impairment in multiple sclerosis: position paper |
| Q40445678 | Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. |
| Q82832609 | Truly benign multiple sclerosis is rare: let's stop fooling ourselves--yes |
| Q44735512 | Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. |
Search more.